Introduction {#Sec1}
============

Patients with head and neck squamous cell carcinomas (HNSCC) could benefit from reliable pretreatment identification of radio-insensitive tumors. This would enable patient selection for primary surgery, avoiding the surgical challenges and morbidity induced by previous irradiation \[[@CR1]\].

Several studies investigated the correlation of pretreatment apparent diffusion coefficient (ADC) and local tumor recurrence after (chemo)radiotherapy ((C)RT) \[[@CR2]--[@CR7]\]. Most studies concluded that tumors with a relatively high pretreatment ADC have a higher chance of local recurrence \[[@CR2]--[@CR4]\]. However, many of these studies did not account for clinical factors such as T-stage, which is known to be an important prognostic factor for local recurrence \[[@CR8]\]. Therefore, the aim of the current study is to find the added value of ADC to clinical T-stage as a prognostic factor for local recurrence of HNSCC.

Methods and materials {#Sec2}
=====================

An extended explanation of the methods used in this study can be found in the [supplemental materials](#Sec10){ref-type="sec"}.

This retrospective study was approved by the institutional review board and the need for informed consent was waived. In total, 217 patients with HNSCC treated with (chemo) radiotherapy were analyzed in the study. Patients were treated between April 2009 and December 2015. All patients underwent diffusion-weighted MRI prior to treatment (Table S[1](#MOESM1){ref-type="media"}). Available *b* values differed across scans with all containing at least a high (*b*800 or *b*1000 s/mm^2^) and a low (*b*0 s/mm^2^) *b* value. Median ADC values of all tumors were obtained using a semi-automatic delineation method. The outcome under investigation, local recurrence, was determined by biopsy (*n* = 40), by progression of a suspected recurrence (*n* = 11) or by death of the patient during recurrence workup (*n* = 7). All other patients were considered to have local control. Patients were followed up for 3 years. To determine the added value of ADC to clinical T-stage as a prognostic factor for local recurrence, univariable models containing ADC and T-stage were compared with a multivariable model containing both variables.

Results {#Sec3}
=======

Patients {#Sec4}
--------

A diagram showing the flow of patients is provided in the supplemental material (Fig. S[1](#MOESM1){ref-type="media"}).

Of the 217 analyzed patients (Table [1](#Tab1){ref-type="table"}), 14 patients (6.5%) were lost to follow-up within 3 years. Fifty-eight patients (27%) developed a local recurrence within 3 years. See S2 for an example of the DW-MRI of one of the patients.Table 1Baseline patient characteristics (*N* = 217)Variable*N*%Age in years63 (40--87)\*Sex  Female5525  Male16275Tumor site  Larynx6932  Hypopharynx3516  Oropharynx10247  Oral cavity115AJCC tumor stage^a^  T28137  T37133  T4a5324  T4b126Nodal stage  N09544  N12612  N2a21  N2b5324  N2c4119HPV status oropharyngeal tumors  Positive1818  Negative6261  Unknown2221Days between MRI and start treatment\*18 (1--63)Treatment  Radiotherapy only12055  Radiotherapy + cisplatin6631  Radiotherapy + cetuximab3114Months of follow-up\*34 (2--102)^a^*AJCC*, American Joint Committee on Cancer 7th edition\*Median (range)

Predictive value of ADC and T-stage for local control {#Sec5}
-----------------------------------------------------

No significant difference in tumor ADC between the groups with local recurrence and those with local control was found 3 years after (C)RT: The mean of median ADC values ± SD was 1.01 ± 0.18 (× 10^−3^ mm^2^/s) in the group with local recurrence and 1.00 ± 0.24 (× 10^−3^ mm^2^/s) (*p* = 0.72) in the group without local recurrence (S3).

The most discriminating cutoff value of ADC was 0.90 × 10^−3^ mm^2^/s. The group of patients with an ADC value higher than this value had no significant difference in the rate of local recurrence compared with the group with ADC values lower than this value (*p* = 0.09) (S4).

The rate of local recurrence was different for each T-stage; patients with T2 or T3 tumors had a significantly lower rate of tumor recurrence than the patients with T4a or T4b tumors (*p* \< 0.01) (S5).

Cox regression showed that T-stage was associated with local recurrence (Table S[2](#MOESM1){ref-type="media"}). The accuracy of the model expressed as the AUC was 0.66 (CI95% 0.57--0.74). In the multivariable Cox regression model containing both T-stage and ADC values, ADC was not independently associated with local recurrence (Table S[3](#MOESM1){ref-type="media"}). The AUC of this model was 0.66 (CI95% 0.58--0.74) while the AUC based solely on ADC was 0.53 (CI95% 0.45--0.62) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1ROC curve displaying the performance of the models containing T-stage and ADC as individual parameters (black and yellow) and the performance of the model containing both variables (blue)

HPV and ADC {#Sec6}
-----------

Of the 102 patients with oropharyngeal carcinoma, 18 had HPV-positive tumors and 62 were negative for HPV. The HPV status of the 22 remaining patients was unknown. HPV-positive tumors had a significantly lower ADC value compared with HPV-negative tumors, 0.81 × 10^−3^ mm^2^/s compared with 0.97 × 10^−3^ mm^2^/s (*p* \< 0.01), respectively. No local recurrences were detected in the HPV-positive group and 18 recurrences occurred in the HPV-negative group. Removing the 18 HPV-positive patients from the total sample of 217 patients and retesting the predictive value of ADC and volume did not change the final conclusions.

Importance of findings {#Sec7}
======================

The findings of our study imply that measuring pretreatment ADC does not help clinicians to predict a future local recurrence when T-stage is already known. This is unfortunate as a relatively easily obtainable quantitative tumor characteristic such as pretreatment ADC would be very helpful in recurrence prediction. The change in ADC (∆ADC) between pretreatment ADC and ADC values obtained during treatment might have more prognostic value \[[@CR5], [@CR7], [@CR9]\].

Discussion {#Sec8}
==========

In contrast to our study, an association between pretreatment ADC and local recurrence has previously been described \[[@CR2]--[@CR4]\]. Most of these studies included a substantially lower amount of patients in comparison with our study. Only the study reported by Lambrecht et al \[[@CR4]\] had a comparable sample size. This study included 161 patients and performed multivariable analysis including, amongst others, tumor ADC and tumor volume. Additionally, similar to our methodology, they created two models, one with ADC included and one without ADC and compared the performance of the models. They report an AUC, used to determine the discriminatory capacity of the first model, of 0.62 (CI95% 0.56--0.70), while for the model without ADC, the AUC is 0.60 (CI95% 0.55--0.67). These results are very similar to our findings and it supports our conclusion that ADC has no added value as a prognostic factor for local recurrence to, more easily obtainable, clinical parameters. A full discussion of the results can be found in the [supplemental material](#Sec10){ref-type="sec"}.

Conclusion {#Sec9}
==========

In this study, we found pretreatment ADC to have no added value to clinical T-stage as a prognostic factor for local recurrences of HNSCC within 3 years after (chemo)radiotherapy.
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ADC

:   Apparent diffusion coefficient

AUC

:   Area under the curve

CI95%

:   95% confidence interval

(C)RT

:   (Chemo)radiotherapy

DW-MRI

:   Diffusion-weighted MRI

HNSCC

:   Head and neck squamous cell carcinoma

HPV

:   Human papilloma virus

ROC

:   Receiver operating characteristic
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